News
CDT
1.850
-7.73%
-0.155
Weekly Report: what happened at CDT last week (0504-0508)?
Weekly Report · 1d ago
CDT Equity Unit Sarborg Files Parent Covering Two Established Compounds Within The Cystic Fibrosis Market
Benzinga · 4d ago
CDT Equity announces AZD5904 progresses into patent cooperation treaty phase
TipRanks · 5d ago
CDT advances AZD5904 into global PCT patent phase
PUBT · 5d ago
Weekly Report: what happened at CDT last week (0427-0501)?
Weekly Report · 05/04 10:12
CDT Equity director Ulrik K. Olsen files initial beneficial ownership statement
PUBT · 05/01 00:17
CDT Equity Announces Board Changes and New Chairperson
TipRanks · 04/27 20:30
CDT Equity appoints Ulrik Olsen to board after Lewis-Hall resignation
PUBT · 04/27 20:12
CDT Equity management to meet with Maxim
TipRanks · 04/27 16:25
Weekly Report: what happened at CDT last week (0420-0424)?
Weekly Report · 04/27 10:14
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 04/24 21:05
CDT Equity files to sell 5.35M shares of common stock for holders
TipRanks · 04/22 10:10
CDT EQUITY - FILES FOR OFFERING OF UP TO 5.35 MLN SHARES OF COMMON STOCK - SEC FILING
Reuters · 04/22 10:05
CDT Equity management to meet with Maxim
TipRanks · 04/20 17:25
Weekly Report: what happened at CDT last week (0413-0417)?
Weekly Report · 04/20 10:11
CDT Equity publishes corporate presentation on AI-driven drug development and out-licensing strategy
PUBT · 04/16 16:16
CDT Equity expands multi-pathway value creation strategy across pharma, IP
TipRanks · 04/16 12:47
CDT Equity targets out-licensing growth via AI-driven indication discovery and solid-form IP
PUBT · 04/16 12:35
CDT Equity FY25 operating loss widens 139% to $36.8 million
PUBT · 04/15 21:02
What's Going On With CDT Equity Shares On Monday?
Benzinga · 04/13 16:38
More
Webull provides a variety of real-time CDT stock news. You can receive the latest news about CDT Equity through multiple platforms. This information may help you make smarter investment decisions.
About CDT
CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. It applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention.